Cargando…
The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing
Contributing to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical treatment, a drug library encompassing approximately 3,142 clinical-stage or FDA-approved small molecules is profiled to identify the candidate therapeutic inhibitors targeting nucleocapsid protein (N) and spike pr...
Autores principales: | Hu, Xuqiao, Zhou, Zhenru, Li, Fei, Xiao, Yang, Wang, Zhaoyang, Xu, Jinfeng, Dong, Fajin, Zheng, Hairong, Yu, Rongmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919521/ https://www.ncbi.nlm.nih.gov/pubmed/33688584 http://dx.doi.org/10.1016/j.heliyon.2021.e06387 |
Ejemplares similares
-
Antibody detection of SARS-CoV spike and nucleocapsid protein
por: Chang, Mau-Sun, et al.
Publicado: (2004) -
The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
por: Yu, Haiyun, et al.
Publicado: (2023) -
Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays
por: Rikhtegaran Tehrani, Zahra, et al.
Publicado: (2020) -
Identification of Conserved Epitopes in SARS-CoV-2 Spike and Nucleocapsid Protein
por: Forcelloni, Sergio, et al.
Publicado: (2021) -
Clinical Trials of Repurposed Antivirals for SARS-CoV-2
por: Martinez, Miguel Angel
Publicado: (2020)